Posters

Two one time use valve strategies have been successfully demonstrated in a completely sealed assay chip. They were also shown to be feasible for on chip reagent storage.

The AAA ATPase p97 is a critical factor in maintaining protein homeostasis in eukaryotic cells. Two probe compounds ML240 and ML241 were developed that both inhibit p97 ATPase activity with an IC50 of approximately 100 nM, and block degradation of p97-dependent proteasome substrate with an IC50 of approximately 900 nM and 3500 nM, respectively. They specifically targeted p97, exhibited markedly different potencies for activating executioner caspases and blocking cell growth.

Detection of Gs- and Gi-coupled GPCR second messenger signal activity has been traditionally accomplished using endpoint assays such as radioactive binding or cAMP assays that require cell lysis. This poster demonstrates the use of the modified luminescent firefly luciferase-based Promega GloSensor™ cAMP Assay on the FLIPR® Tetra system to enable detection of cAMP mediated Gs- and Gi-coupled GPCR activity in a true kinetic assay.

Neurotoxicity can cause temporary or permanent damage of brain or peripheral nervous system and has been found to be a major cause of neurodegenerative diseases such as Alzheimer’s or Parkinson’s. Accordingly, there is a great interest in developing more predictive, disease relevant cell-based models and efficient screening tools for assessing the neurotoxicity of chemical compounds, drug candidates and environmental agents.

Transcreener® ADP2 Assays are homogenous assays with fluorescent readouts that enable the detection and screening of established drug targets including protein and lipid kinases, as well as emerging targets such as carbohydrate kinases, triphosphatases, heat shock proteins and other ATPases.

A large percentage of new drugs fail in clinical studies due to cardiac toxicity. Development of highly predictive in vitro assays suitable for screening, safety assessment or other environments is therefore extremely important for drug development. Human cardiomyocytes derived from stem cell sources can greatly accelerate the discovery of cardiac drugs and improve drug safety by offering more clinically relevant cell-based models than those presently available.

Inflammation is accompanied by increased endothelial chemokine production and adhesion molecule expression, which may result in an extensive neutrophil infiltration. As such, the search for novel anti-inflammatory substances able to downregulate these parameters, as well as tissue damage, holds therapeutic promise.

High Performance Chip Data Analysis (HPCDA) improves expression profiling of Affymetrix chips via Bioretis database: you can easily use the default parameters and are sure to get the optimum of true positive results, independant of number of significant genes in your dataset. Gene List Significance Index (GLSI) quantifies quality of gene lists. With GLSI its easily judged which normalization/analyzing method gives better results. HPCDA score ranks by relevance.

Several methods have been developed for target labelling to enable DNA microarray quantification without taking careful consideration for target length effect. This report highlights the importance of choosing the optimum target length that would ensure specificity without compromising sensitivity of the assay. It also shows the advantages of using the modified PCR method over other methods in generating labelled amplicons of the desired lengths to maximize hybridization efficiency.